Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

Midatech Appoints Dr Jim Phillips as Chief Executive Officer

Published: Wednesday, October 02, 2013
Last Updated: Wednesday, October 02, 2013
Bookmark and Share
Dr Philips has over 25 years of senior management and Board level experience in public and private companies across Europe, the US and Australia.

During this time he has accumulated considerable expertise in M&A and licensing deal origination and execution, which he now brings to the role of CEO of Midatech.

Dr Phillips joins Midatech from Healthcare Brands International Ltd (HBI), the UK consumer healthcare company, where he has been CEO since 2010. Between 2007 and 2012 he served as Non-executive Chairman of Prosonix Ltd, a specialty pharmaceutical company developing respiratory medicines using an innovative particle-engineering technology and approach.

Before joining HBI, Dr Phillips was CEO of Vantia Ltd., a pharmaceutical company developing novel, small molecule drugs. Prior to that he founded and served as CEO of Talisker Pharma until its acquisition by EUSA in 2006, upon which he became President of EUSA Pharma Europe and an Executive Board Member EUSA Pharma Inc. Dr Phillips has also held senior roles in drug and business development in Novartis and Johnson & Johnson.

Commenting on the appointment, Professor Thomas Rademacher, Chairman of Midatech said: “I am very pleased to welcome Jim to the Company as our new CEO. I have no doubt his senior management and commercial experience within the Biotechnology sector will help us sign the partnership deals and raise the funds we need to deliver the significant potential of our unique gold-nanoparticle technology.”

Dr Philips added: “I am excited to have joined Midatech at this crucial stage as it accelerates the development and commercialisation of its novel gold nanoparticle technology. With its potential to greatly improve the delivery of important drugs for the treatment of diabetes and various cancer types, as well as uses in medical diagnostics and imaging, I am confident that Midatech will generate significant growth and value over the next several years.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Midatech Announces the Opening of cGMP Standard Facility
Midatech Biogune S.L. is said to be the world’s first cGMP grade manufacturing plant for the production of nanoparticles at a scale commensurate with pharmaceutical applications.
Monday, May 07, 2007
Scientific News
Tolerant Immune System Increases Cancer Risk
Researchers have found that individuals with high immunoCRIT ratios may have an increased risk of developing certain cancers.
Developing a Gel that Mimics Human Breast for Cancer Research
Scientists at the Universities of Manchester and Nottingham have been funded to develop a gel that will match many of the biological structures of human breast tissue, to advance cancer research and reduce animal testing.
New Gene Therapy for Vision Loss From a Mitochondrial Disease
NIH-funded study shows success in targeting mitochondrial DNA in mice.
Predictive Model for Breast Cancer Progression
Biomedical engineers have demonstrated a proof-of-principle technique that could give women and their oncologists more personalized information to help them choose options for treating breast cancer.
Specific Variations in RNA Splicing Linked to Breast Cancer
Researchers have identified cellular changes that may play a role in converting normal breast cells into tumors. Targeting these changes could potentially lead to therapies for some forms of breast cancer.
Gene Expression: A Snapshot of Stem Cell Development
New genes found that regulate development of stem cells.
Assessing Cancer Patient Survival and Drug Sensitivity
RNA editing events another way to investigate biomarkers and therapy targets.
Editing Genes to Create HIV Killers
Seattle scientists have managed to genetically transform human cells in the lab from HIV targets to HIV killers, and the technique could have implications for cancer and other diseases.
Researchers Disguise Drugs As Platelets to Target Cancer
Researchers have for the first time developed a technique that coats anticancer drugs in membranes made from a patient’s own platelets.
A New Single-Molecule Tool to Observe Enzymes at Work
A team of scientists at the University of Washington and the biotechnology company Illumina have created an innovative tool to directly detect the delicate, single-molecule interactions between DNA and enzymatic proteins.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos